🏅 FDA Orphan Designation
Redemplo
plozasiran
Manufacturer: Arrowhead Pharmaceuticals, Inc.
Indicated for:
FDA-Approved Indications (1)
Familial chylomicronemia syndromeOrphan Designation
as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS)
Indications & Usage
as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS)
💙 Support Programs
View all →Redemplo
Arrowhead Pharmaceuticals, Inc.
REDEMPLO
Unknown
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.